Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UDCA for symptomatic polycystic liver disease
2013-003207-19Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ursodeoxycholic acid in Polycystic liver disease (PLD) and autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Proportional change in total liver volume at 6 months. Started Aug 2013; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
Polycystic liver disease (PLD)autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2013-003207-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003207-19.